Anormed, Inc.

Genzyme Corporation

Johnson Matthey Public Limited Company

The General Hospital Corporation

Smithkline Beecham Corporation

Ortho Pharmaceutical Corporation

Johnson Matthey Inc.

Shire International Licensing B.v.

Johnson Matthey Public Limted Company

University of Washington

Genzyme Global S.à.r.l.

Gary James Bridger

Renato Skerlj

Dominique Schols

David Earl Bogucki

Ernest John McEachern

Curtis Harwig

Al Kaller

Yuanxi Zhou

Siqiao Nan

Jason B Crawford

Trevor R Wilson

Bem Atsma

Christopher Dennis Smith

Maria Rosaria Di Fluri

Michael J Abrams

Eva Maria Boehringer

Zhongren Wang

Geoffrey W Henson

Ronald Trevor MacFarland

Wen Yang

Gary B Calandra

Yongbao Zhu

Hal E Broxmeyer

Markus Metz

Gang Chen

Renato Tony Skerlj

Ian R Baird

David C Dale

Krystyna A Skupinska

Bern Atsma

Renato T Skerlj

Christopher Dennis

Rosaria Maria Di Fluri

Krystyna Skupinska

Sreenivasan Padmanabhan

David Aaron Schwartz

John D Higgins, Iii

Tong-Shuang Li

Scott K Larsen

Elyse Bourque

Jonathan Langille

Andrew W Millar

Pedro E Hernandez

Sreenivasan Padmanbhan

Ernest J Mceachern

Alan J Fischman

Robert H Rubin

Alison Mary Badger

H William Strauss

Daniel J Kroon

Claudia K Derian

Howard F Solomon

Simon P Fricker

Renato T Skelj

Stefan R Idzan

David M Thornton

Michael E Ultee

Milind P Sant

Pedro E Hernandez-Abad

Maria Rosario DiFluri

Anthony J Fuccello

Ronald Trevor Macfarland

Trevor Wilson

C David Dale

Siquiao Nan

Dale C David David

Frank J Hsu

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formulaZ-linker-Z'&#x2003;&#x2003;(1) 

Methods to mobilize progenitor/stem cells

Polyamine macrocyclic compounds, e.g. of 10 to 15 ring members and 3 to 6 ring amine nitrogens, linked through methylene groups to an aromatic moiety, show high selective activity against HIV.

Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity

The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R, Rand Rare substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

CXCR4 chemokine receptor binding compounds

Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.

Chemokine receptor binding heterocyclic compounds

The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.

CXCR4 antagonists

Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCRreceptor.

Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Chemokine receptor binding compounds

This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.

Synthesis of enantiomerically pure amino-substituted fused bicyclic rings

Methods to modulate conditions mediated by the CXCR4 receptor

Tertiary amine compounds that bind chemokine receptors such as CXCR4 and CCR5 are disclosed.

Growing community of inventors

Bellingham, WA, United States of America

Gary James Bridger